Skip to main content
. Author manuscript; available in PMC: 2012 Sep 1.
Published in final edited form as: Surgery. 2011 Sep;150(3):466–473. doi: 10.1016/j.surg.2011.07.006

Table 4.

Tumor Response, including 95% confidence interval from the random effect model and number of studies in each group.

Group Complete Response Partial Response Stable Disease Progressive Disease
All patients 1.8% [0.6%, 3.6%]
I2 = 35.1% [0.0%, 68.1%]
(n=330)		 18.8% [9.7%, 29.9%]
I2 = 81.8% [68.6%, 89.5%]
(n=330)		 59.2% [46.1%, 71.6%]
I2 = 81.9% [68.8%, 89.5%]
(n=330)		 18.9% [13.1%, 25.4%]
I2 = 49.9% [0.1%, 74.9%]
(n=330)
Group A (resectable before treatment) 0.8% [0.0%, 2.6%]
I2 = 0.0% [0.0%, 0.0%]
(n=196)		 9.5% [2.9%, 19.4%]
I2 = 72.8% [37.3%, 88.2%]
(n=196)		 73.9% [63.2%, 83.3%]
I2 = 58.2% [0.0%, 83.1%]
(n=196)		 17.0% [11.9%, 22.7%]
I2 = 0.0% [0.0%, 69.6%]
(n=196)
Group B (borderline/unresectable before treatment) 4.0% [0.3%, 11.6%]
I2 = 65.1% [8.6%, 86.7%]
(n=134)		 31.8% [24.2%, 39.8%]
I2 = 45.0% [0.0%, 79.8%]
(n=134)		 40.9% [32.8%, 49.3%]
I2 = 27.1% [0.0%, 71.2%]
(n=134)		 21.8% [10.1%, 36.5%]
I2 = 72.1% [29.6%, 88.9%]
(n=134)